Kanglong Chemical (Beijing) Co., Ltd. (hereinafter referred to as "the Company") disclosed the "Quality Return Dual Improvement" action plan announcement on March 7, 2024. In 2025, the Company will continue to prioritize investors by focusing on core business, enhancing core competitiveness, standardizing corporate governance, fulfilling social responsibilities, improving information disclosure quality, strengthening communication with investors, and enhancing investor returns. The main work content is as follows:
1. Continuously Build a Comprehensive, Integrated, Internationalized, and Multi-Therapy Drug R&D Service Platform
In 2025, the Company will firmly implement the core strategy of "comprehensive, integrated, internationalized, and multi-therapy," focusing on customer needs, continuing to improve global layout, and strengthening advanced technology platform construction. Overall business has maintained a steady and healthy development trend. In 2025, the Company achieved operating revenue of 1,409,507.87 thousand yuan, a year-on-year increase of 14.82%; net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 153,832.90 thousand yuan, a year-on-year increase of 38.85%; net cash flow from operating activities was 322,104.72 thousand yuan, a year-on-year increase of 25.01%; after deducting capital expenditures invested to support business development, the Company’s free cash flow was 55,196.94 thousand yuan; new order amounts increased by over 14% year-on-year; more than 950 new customers were added, serving over 3,300 global clients. While steadily growing the business, the Company is advancing mergers and acquisitions around the core strategy of an integrated R&D service platform and enhancing service capabilities through business integration, incorporating top drug R&D talent and advanced facilities into the Company’s integrated service platform to improve R&D efficiency. In February 2025, the Company acquired a controlling stake in Zhejiang Haixin Zhihui Technology Co., Ltd., completing equity restructuring in the first quarter of 2026, establishing an independent division at the group level to further deepen the Company’s life and health full-chain service strategy. In the fourth quarter of 2025, the Company acquired a controlling stake in Wuxi Bai'ao De Biological Sciences Co., Ltd., further strengthening the Company’s service capabilities in structural biology, complex drug target protein preparation, and analysis. In 2025, in the field of innovative drug R&D, artificial intelligence technology continues to move from concept to application. The Company actively embraces technological development and transformation, continuously deepening the digital and intelligent construction of the R&D service platform. The Company focuses on investing in automation and AI technology, deeply integrating it into all aspects of drug R&D, aiming to improve experimental throughput, enhance service efficiency, and reduce operational errors, providing clients with faster, more accurate, and reliable R&D data. At the same time, the Company has signed cooperation agreements with well-known domestic and foreign universities to accelerate the transformation of more potential digital medical, biopharmaceutical, and life health technology solutions, jointly promoting high-quality development in the life sciences industry. In 2026, the Company will continue to adhere to the development strategy of "comprehensive, integrated, internationalized, and multi-therapy," strengthening the layout and application of new technologies, committed to providing better services to clients and gaining more market share. The Company will focus on the following key tasks:
- Vigorously strengthen the construction of a multi-therapy full-process new drug R&D service platform;
- Further enhance synergy through project management;
- Fully strengthen business and market development capabilities, emphasizing customer relationship management;
- Continue to strengthen talent reserves to support long-term sustainable development;
- Systematically enhance risk governance capabilities;
- Emphasize technology and embrace AI.